Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Porth, Isabel; Hirsch, Daniela; Ceribas, Yonca; Weidner, Philip; Weichert, Wilko; Götze, T.O.; Perner, Sven; Luley, Kim; Heyer, Christian Moritz; Torre, Carolina De La; Hofheinz, Ralf–Dieter; Lorenzen, Sylvie; Gaiser, Timo

doi:10.1016/j.ejca.2023.01.022

Cited by 3 publications

(2 citation statements)

References 42 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Patient*innen erhielten eine Therapie über 18 Wochen. Unter der anschließenden Erhaltungstherapie mit Trastuzumab wurden Langzeitremissionen beschrieben, eine Korrelation mit prognostischen Biomarkern wurde kürzlich veröffentlicht [31].…”

Section: Definitionunclassified

Medikamentöse Therapiestrategien des Magenkarzinoms

Scheck,

Lorenzen

2024

TumorDiagnostik & Therapie

Self Cite

View full text Add to dashboard Cite

Magenkarzinome sind in Deutschland bei Frauen für 2,4% und bei Männern für 3,5% der Krebsneuerkrankungen verantwortlich und gehen mit einer hohen Letalitätsrate einher. In der Therapie wird zwischen einer lokalen und einer metastasierten Tumorerkrankung unterschieden. Neue Behandlungsverfahren wie Immuntherapie und zielgerichtete Therapie halten in beiden Fällen Einzug in die derzeitigen Therapiestrategien und verbessern damit die Prognose der Patient*innen.

show abstract

Section: Definitionunclassified

Medikamentöse Therapiestrategien des Magenkarzinoms

Scheck,

Lorenzen

2024

TumorDiagnostik & Therapie

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, a retrospective biomarker analysis revealed that patients with a prolonged PFS under trastuzumab maintenance have higher PD-L1 CPS scores, which correlate with increased CD4+ memory T cells. The tumor mutational burden, ERBB2 score or resistance-associated genetic alterations (see below) did not differ between short-term and long-term responders [17]. Attempts to further improve maintenance strategies have not led to success so far.…”

Section: Introduction Of Trastuzumabmentioning

confidence: 96%

HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

Scheck,

Hofheinz,

Lorenzen

2024

Cancers

Self Cite

View full text Add to dashboard Cite

Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.

show abstract

Medikamentöse Therapiestrategien des Magenkarzinoms

Scheck,

Lorenzen

2023

Gastroenterologie up2date

View full text Add to dashboard Cite

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Cited by 3 publications

References 42 publications

Medikamentöse Therapiestrategien des Magenkarzinoms

Medikamentöse Therapiestrategien des Magenkarzinoms

HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

Medikamentöse Therapiestrategien des Magenkarzinoms

Contact Info

Product

Resources

About